Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday’s regular session. Trading volume for…
Dow Tumbles 150 Points; Crude Oil Falls Sharply
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday.
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
Unicycive Therapeutics Inc’s (NASDAQ:UNCY) pivotal bioequivalence (BE) study comparing Renazorb to Fosrenol has met the primary endpoint. Renazorb is an…
Unicycive Achieves Primary Endpoint In Pivotal Bioequivalence Study Of Renazorb
Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol
Renazorb's enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient
Unicycive Issued Notice Of Acceptance To Initiate Phase 1 Study Of UNI-494 Following Review Of Clinical Trial Application By The Medicines And Healthcare Products Regulatory Agency In The United Kingdom
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Ed Arce maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $9 to $8.
